Phosphorus 32 in Treating Patients With Glioblastoma Multiforme

Status unconfirmed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Radioactive drugs such as phosphorus 32 may be able to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of phosphorus 32 in treating patients with glioblastoma multiforme.

Key facts

Study ID

NCT00004129

Run by

Center for Molecular Medicine

People needed

12

Starts

1999-09-01

Last updated by the study team

2013-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Center for Molecular Medicine — Garden City, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.